Trial · NCT05825573
Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus
NCT05825573, Phase 3, Active not recruiting, Centre Hospitalier Universitaire de Nīmes
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus. Trials, record NCT05825573. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05825573
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus
- NCT number
- NCT05825573
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 340 participants, estimated
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Conditions
- Intracardiac Thrombus, STEMI, Heart Failure
- Interventions
- Vitamin K antagonist, Direct oral anticoagulant
- First posted
- 2023-04-24
- Last updated
- 2026-02-17
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Net clinical benefit of DOA in comparison to VKA in patients with intra-cardiac thrombus | 6 months | Composite endpoint of all-cause death, myocardial infarction, stroke, acute peripheral emboli, acute pulmonary embolism, thrombus persistence and clinically relevant bleedings (BARC 2 to 5 bleedings) |
| Secondary | All cause death between groups | 6 months | Any death documented during the follow-up independently of cause of death |
| Secondary | All cause death between groups | 12 months | Any death documented during the follow-up independently of cause of death |
| Secondary | Myocardial infarction occurrence between groups | 6 months | All non-fatal MI, excluding MI type 3, which will be captured separately as death |
| Secondary | Myocardial infarction occurrence between groups | 12 months | All non-fatal MI, excluding MI type 3, which will be captured separately as death |
| Secondary | Stroke occurrence between groups | 6 months | Classified as Transient ischemic attack (TIA), Ischemic Stroke, Haemorrhagic Stroke and Undetermined Stroke |
| Secondary | Stroke occurrence between groups | 12 months | Classified as Transient ischemic attack (TIA), Ischemic Stroke, Haemorrhagic Stroke and Undetermined Stroke |
| Secondary | Acute peripheral emboli occurrence between groups | 6 months | All acute artery occlusion (limb, renal or digestive artery occlusion confirmed by clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing |
| Secondary | Acute peripheral emboli occurrence between groups | 12 months | All acute artery occlusion (limb, renal or digestive artery occlusion confirmed by clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing |
| Secondary | Acute pulmonary embolism occurrence between groups | 6 months | Defined as partial or complete occlusion of pulmonary artery or one of its branch confirmed by consistent clinical history and supported by evidence of embolism from surgical specimens, autopsy, angiography or vascular imaging in accordance to international guidelines |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 32273033 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05825573
GET https://conductscience.org/api/trials/v1/NCT05825573/registered?page=2